Molecular monitoring in CML-a modern example of an old proverb.
No abstract available
COI Statement
Competing interests: The author declares no competing interests.
References:
Wang Y, Liang ZJ, Gale RP, Liao HZ, Ma J, Gong TJ, et al. Chronic myeloid leukaemia: biology and therapy. Blood Rev. 2024;65:101196. 10.1016/j.blre.2024.101196.
Leak S, Horne GA, Copland M. Targeting BCR-ABL1-positive leukaemias: a review article. Camb Prism Precis Med. 2023;1:e21. 10.1017/pcm.2023.9.
Jin G, Liu K, Guo Z, Dong Z. Precision therapy for cancer prevention by targeting carcinogenesis. Mol Carcinog. 2024. 10.1002/mc.23798.
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7. 10.1200/JCO.2015.66.2866.
Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968. 10.1016/j.blre.2022.100968.